Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr;9(7):557. doi: 10.21037/atm-20-2194

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2021 Annals of Translational Medicine. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

LDN193189 inhibited PDAC growth in vivo. (A) Representative bioluminescent images of orthotopic pancreatic cancer models during the treatment. (B) Bioluminescent densities during the treatment. (C) Tumor images at the end of the treatment, n=5. (D) Representative IHC images showing the expression of BMPR2, GRB2 and Ki67 of tumors. (E) Western blot analysis of the orthotopic tumors. (F) Tumor growth curves of PDX during the treatment. (G) Image of tumors excised from PDX mouse models at the end of the treatment, n=5. (H) Tumor weight analysis of PDX models. (I) Western blot analysis of the PDX tumors. (J,K) Tumor growth after knockdown of BMPR2 by shRNA (n=5). Scale bar represents 1 cm. The data are shown as the mean ± SD. ***, P<0.001. IHC, immunohistochemistry; BMPR2, bone morphogenic protein receptor 2; PDX, patient-derived xenograft; PDAC, pancreatic ductal adenocarcinoma.